Mallinckrodt Announces First Investigator Award for Pioneering Efforts in ECP Immunomodulation

Staines-Upon-Thames, England (ots/PRNewswire) -

EUR50,000 award goes to Rotherham NHS Foundation Trust Department
of Haematology

Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical
company, today announced the inaugural recipient of its Advancing
Extracorporeal Photopheresis (ECP) Immunomodulation Investigator
Award. The winning entry was submitted by investigator Dr. Nick
Matthews and co-investigator Dr. Arun Alfred of the Department of
Haematology at Rotherham NHS Foundation Trust in the United Kingdom.

(Photo: https://mma.prnewswire.com/media/656235/Mallinckrodt.jpg )

Their proposal seeks to establish whether immunomodulation
achieved through extracorporeal photopheresis (ECP) used in treatment
of chronic graft-versus-host disease (GVHD) occurs through mediation
of in vivo macrophage activation. Along with the 2018 Investigator
Award, the Department of Haematology at Rotherham NHS Foundation
Trust will receive an educational grant of EUR50,000 to support this
research. The winner was first revealed at the THERAKOS ECP
Immunomodulation(TM) symposium at the 44th Annual Meeting of the
European Society for Blood and Marrow Transplantation (EBMT) in
Lisbon, Portugal.

Receiving the award at EBMT 2018, on behalf of the Rotherham NHS
Foundation Trust, Dr. Alfred said: "It's an honour to receive the
inaugural Investigator Award and we look forward to sharing the
outcomes of our work in due course."

Mallinckrodt developed the Investigator Award to mark 30 years of
its pioneering THERAKOS ECP Immunomodulation(TM) and it reflects the
company's ongoing commitment to the science of immunomodulation
through ECP and its therapeutic applications. The award recognises
individuals and institutions whose remarkable research contributes to
the advancement of knowledge in this area of medicine.

"Mallinckrodt is a pioneer in ECP immunomodulation and we recently
celebrated the 30th anniversary of THERAKOS," said Steve Romano,
M.D., Executive Vice President and Chief Scientific Officer of
Mallinckrodt. "We are proud to support the work of those who continue
to push boundaries in the field and I congratulate Dr. Alfred and his
team at the Rotherham NHS Foundation Trust on this recognition."

Entries were invited from clinicians and scientists working on
translational or outcomes-based research, as well as collaborative
projects. Submissions were assessed on a range of criteria,
specifically scientific merit, novelty and feasibility.

The 2019 Advancing ECP Immunomodulation Investigator Award will be
open for entries from September 2018. Full details on how to enter
can be found at www.therakos.co.uk.

Mallinckrodt is the world's only provider of approved,
fully-integrated systems for administering immunomodulatory therapy
through ECP. Its Therakos therapeutic platforms, including the latest
generation THERAKOS® CELLEX® Photopheresis System, are used by
academic medical centres, hospitals, and treatment centres in more
than 30 countries and have delivered more than 1 million treatments
globally. For more information, please visit www.therakos.co.uk.

ABOUT MALLINCKRODT

Mallinckrodt is a global business that develops, manufactures,
markets and distributes specialty pharmaceutical products and
therapies. Areas of focus include autoimmune and rare diseases in
specialty areas like neurology, rheumatology, nephrology, pulmonology
and ophthalmology; immunotherapy and neonatal respiratory critical
care therapies; analgesics and gastrointestinal products. The
company's core strengths include the acquisition and management of
highly regulated raw materials and specialized chemistry, formulation
and manufacturing capabilities. The company's Specialty Brands
segment includes branded medicines and its Specialty Generics segment
includes specialty generic drugs, active pharmaceutical ingredients
and external manufacturing. To learn more about Mallinckrodt, visit
www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of
important company information, such as press releases, investor
presentations and other financial information. It also uses its
website to expedite public access to time-critical information
regarding the company in advance of or in lieu of distributing a
press release or a filing with the U.S. Securities and Exchange
Commission (SEC) disclosing the same information. Therefore,
investors should look to the Investor Relations page of the website
for important and time-critical information. Visitors to the website
can also register to receive automatic e-mail and other notifications
alerting them when new information is made available on the Investor
Relations page of the website.

Mallinckrodt, the "M" brand mark and the Mallinckrodt
Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other
brands are trademarks of a Mallinckrodt company or their respective
owners. © 2018 Mallinckrodt Item code: PRC INTL/dvUVA/0318/0066. Date
of preparation: March 2018.

ots Originaltext: Mallinckrodt plc
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Rhonda Sciarra
Senior Communications Manager +1 908-238-6765
rhonda.sciarra@mnk.com Meredith Fischer
Chief Public Affairs Officer +1 314-654-3318
meredith.fischer@mnk.com Investor Relations Daniel J. Speciale
CPA
Investor Relations and Strategy Officer+1 314-654-3638
daniel.speciale@mnk.com

Original-Content von: Mallinckrodt plc, übermittelt durch news aktuell